NCT04208061View on ClinicalTrials.gov

A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 18, 2019

Primary Completion Date

March 25, 2021

Study Completion Date

April 1, 2021

Conditions
Healthy
Interventions
DRUG

Dabigatran Etexilate

Participants will receive single dose of dabigatran etexilate orally.

DRUG

DRV/COBI

Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).

DRUG

Ritonavir

Participants will receive ritonavir orally.

DRUG

Darunavir

Participants will receive Darunavir orally.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04208061 - A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants | Biotech Hunter | Biotech Hunter